Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

Clinical trial NCT00904670 · COMPLETED

Trial details

NCT number: NCT00904670
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Attention Deficit Hyperactivity Disorder

Start date: 2009-04-01
Primary completion: 2009-08-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.